Etiological spectrum of persistent fever in the tropics and predictors of ubiquitous infections: a prospective four-country study with pooled analysis.


Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
02 05 2022
Historique:
received: 25 10 2021
accepted: 21 03 2022
entrez: 1 5 2022
pubmed: 2 5 2022
medline: 4 5 2022
Statut: epublish

Résumé

Persistent fever, defined as fever lasting for 7 days or more at first medical evaluation, has been hardly investigated as a separate clinical entity in the tropics. This study aimed at exploring the frequencies and diagnostic predictors of the ubiquitous priority (i.e., severe and treatable) infections causing persistent fever in the tropics. In six different health settings across four countries in Africa and Asia (Sudan, Democratic Republic of Congo [DRC], Nepal, and Cambodia), consecutive patients aged 5 years or older with persistent fever were prospectively recruited from January 2013 to October 2014. Participants underwent a reference diagnostic workup targeting a pre-established list of 12 epidemiologically relevant priority infections (i.e., malaria, tuberculosis, HIV, enteric fever, leptospirosis, rickettsiosis, brucellosis, melioidosis, relapsing fever, visceral leishmaniasis, human African trypanosomiasis, amebic liver abscess). The likelihood ratios (LRs) of clinical and basic laboratory features were determined by pooling all cases of each identified ubiquitous infection (i.e., found in all countries). In addition, we assessed the diagnostic accuracy of five antibody-based rapid diagnostic tests (RDTs): Typhidot Rapid IgM, Test-it A total of 1922 patients (median age: 35 years; female: 51%) were enrolled (Sudan, n = 667; DRC, n = 300; Nepal, n = 577; Cambodia, n = 378). Ubiquitous priority infections were diagnosed in 452 (23.5%) participants and included malaria 8.0% (n = 154), tuberculosis 6.7% (n = 129), leptospirosis 4.0% (n = 77), rickettsiosis 2.3% (n = 44), enteric fever 1.8% (n = 34), and new HIV diagnosis 0.7% (n = 14). The other priority infections were limited to one or two countries. The only features with a positive LR ≥ 3 were diarrhea for enteric fever and elevated alanine aminotransferase level for enteric fever and rickettsiosis. Sensitivities ranged from 29 to 67% for the three RDTs targeting S. Typhi and were 9% and 16% for the two RDTs targeting leptospirosis. Specificities ranged from 86 to 99% for S. Typhi detecting RDTs and were 96% and 97% for leptospirosis RDTs. Leptospirosis, rickettsiosis, and enteric fever accounted each for a substantial proportion of the persistent fever caseload across all tropical areas, in addition to malaria, tuberculosis, and HIV. Very few discriminative features were however identified, and RDTs for leptospirosis and Salmonella Typhi infection performed poorly. Improved field diagnostics are urgently needed for these challenging infections. NCT01766830 at ClinicalTrials.gov.

Sections du résumé

BACKGROUND
Persistent fever, defined as fever lasting for 7 days or more at first medical evaluation, has been hardly investigated as a separate clinical entity in the tropics. This study aimed at exploring the frequencies and diagnostic predictors of the ubiquitous priority (i.e., severe and treatable) infections causing persistent fever in the tropics.
METHODS
In six different health settings across four countries in Africa and Asia (Sudan, Democratic Republic of Congo [DRC], Nepal, and Cambodia), consecutive patients aged 5 years or older with persistent fever were prospectively recruited from January 2013 to October 2014. Participants underwent a reference diagnostic workup targeting a pre-established list of 12 epidemiologically relevant priority infections (i.e., malaria, tuberculosis, HIV, enteric fever, leptospirosis, rickettsiosis, brucellosis, melioidosis, relapsing fever, visceral leishmaniasis, human African trypanosomiasis, amebic liver abscess). The likelihood ratios (LRs) of clinical and basic laboratory features were determined by pooling all cases of each identified ubiquitous infection (i.e., found in all countries). In addition, we assessed the diagnostic accuracy of five antibody-based rapid diagnostic tests (RDTs): Typhidot Rapid IgM, Test-it
RESULTS
A total of 1922 patients (median age: 35 years; female: 51%) were enrolled (Sudan, n = 667; DRC, n = 300; Nepal, n = 577; Cambodia, n = 378). Ubiquitous priority infections were diagnosed in 452 (23.5%) participants and included malaria 8.0% (n = 154), tuberculosis 6.7% (n = 129), leptospirosis 4.0% (n = 77), rickettsiosis 2.3% (n = 44), enteric fever 1.8% (n = 34), and new HIV diagnosis 0.7% (n = 14). The other priority infections were limited to one or two countries. The only features with a positive LR ≥ 3 were diarrhea for enteric fever and elevated alanine aminotransferase level for enteric fever and rickettsiosis. Sensitivities ranged from 29 to 67% for the three RDTs targeting S. Typhi and were 9% and 16% for the two RDTs targeting leptospirosis. Specificities ranged from 86 to 99% for S. Typhi detecting RDTs and were 96% and 97% for leptospirosis RDTs.
CONCLUSIONS
Leptospirosis, rickettsiosis, and enteric fever accounted each for a substantial proportion of the persistent fever caseload across all tropical areas, in addition to malaria, tuberculosis, and HIV. Very few discriminative features were however identified, and RDTs for leptospirosis and Salmonella Typhi infection performed poorly. Improved field diagnostics are urgently needed for these challenging infections.
TRIAL REGISTRATION
NCT01766830 at ClinicalTrials.gov.

Identifiants

pubmed: 35491421
doi: 10.1186/s12916-022-02347-8
pii: 10.1186/s12916-022-02347-8
pmc: PMC9059373
doi:

Substances chimiques

Antibodies, Bacterial 0
Immunoglobulin G 0
Immunoglobulin M 0

Banques de données

ClinicalTrials.gov
['NCT01766830']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

144

Informations de copyright

© 2022. The Author(s).

Références

Clin Infect Dis. 2018 Aug 1;67(4):628-638
pubmed: 29522159
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0004818
pubmed: 27812101
Clin Microbiol Infect. 2018 Aug;24(8):806-807
pubmed: 29940346
JAC Antimicrob Resist. 2020 Jul 07;2(3):dlaa039
pubmed: 34240055
BMC Med. 2020 Sep 21;18(1):279
pubmed: 32951596
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0004749
pubmed: 27812090
BMC Med. 2020 Sep 21;18(1):294
pubmed: 32951589
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
Emerg Microbes Infect. 2019;8(1):339-352
pubmed: 30866787
BMJ. 2018 Nov 29;363:k4766
pubmed: 30498133
BMC Infect Dis. 2019 Jul 4;19(1):577
pubmed: 31272417
Clin Microbiol Infect. 2018 Aug;24(8):808-814
pubmed: 29454844
J Infect Dis. 2018 Nov 10;218(suppl_4):S255-S267
pubmed: 30307563
Medicine (Baltimore). 2007 Jan;86(1):18-25
pubmed: 17220752
PLoS One. 2016 Aug 03;11(8):e0160278
pubmed: 27486746
Am J Trop Med Hyg. 2017 Nov;97(5):1454-1460
pubmed: 28820708
PLoS Negl Trop Dis. 2018 May 31;12(5):e0006477
pubmed: 29852003
PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0004654
pubmed: 27812089
Curr Opin Infect Dis. 2016 Oct;29(5):433-9
pubmed: 27429138
Clin Microbiol Infect. 2013 May;19(5):422-31
pubmed: 23413992
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008264
pubmed: 22336839
PLoS Negl Trop Dis. 2015 Aug 14;9(8):e0003971
pubmed: 26274584
PLoS Negl Trop Dis. 2019 May 8;13(5):e0007303
pubmed: 31067228
Clin Microbiol Infect. 2018 Aug;24(8):827-835
pubmed: 29777926
Indian J Med Res. 2018 Oct;148(4):385-395
pubmed: 30666001
BMC Med. 2020 Sep 21;18(1):299
pubmed: 32951591
PLoS Negl Trop Dis. 2020 Sep 14;14(9):e0008641
pubmed: 32925913
Clin Microbiol Infect. 2018 Aug;24(8):815-826
pubmed: 29581051
BMJ Open. 2020 Jul 21;10(7):e035632
pubmed: 32699131
Clin Microbiol Infect. 2019 Apr;25(4):437-444
pubmed: 30472422
Lancet Infect Dis. 2018 Aug;18(8):e248-e258
pubmed: 29519767
BMJ. 2004 Jul 17;329(7458):168-9
pubmed: 15258077
Acta Trop. 2020 Jan;201:105183
pubmed: 31542372
PLoS Negl Trop Dis. 2015 Sep 14;9(9):e0003899
pubmed: 26368568
BMC Med. 2020 Jan 3;18(1):1
pubmed: 31898501
Cochrane Database Syst Rev. 2019 Aug 01;8:CD011871
pubmed: 31425612

Auteurs

Emmanuel Bottieau (E)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. ebottieau@itg.be.

Lukas Van Duffel (L)

Infectious Diseases Operative Unit, Santa Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy.

Sayda El Safi (S)

Faculty of Medicine, University of Khartoum, Khartoum, Sudan.

Kanika Deshpande Koirala (KD)

B. P. Koirala Institute of Health Sciences, Dharan, Nepal.

Basudha Khanal (B)

B. P. Koirala Institute of Health Sciences, Dharan, Nepal.

Suman Rijal (S)

B. P. Koirala Institute of Health Sciences, Dharan, Nepal.

Narayan Raj Bhattarai (NR)

B. P. Koirala Institute of Health Sciences, Dharan, Nepal.

Thong Phe (T)

Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia.

Kruy Lim (K)

Sihanouk Hospital Center of HOPE, Phnom Penh, Cambodia.

Deby Mukendi (D)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
Service de neurologie, Université de Kinshasa, Kinshasa, Democratic Republic of Congo.

Jean-Roger Lilo Kalo (JL)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.

Pascal Lutumba (P)

Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.

Barbara Barbé (B)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Jan Jacobs (J)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Marjan Van Esbroeck (M)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Nikki Foqué (N)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Achilleas Tsoumanis (A)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.

Philippe Parola (P)

IHU-Méditerranée Infection & Aix-Marseille University, Marseille, France.

Cedric P Yansouni (CP)

JD MacLean Centre for Tropical Diseases, McGill University Health Centre, Montreal, Canada.

Marleen Boelaert (M)

Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.

Kristien Verdonck (K)

Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.

François Chappuis (F)

Division of Tropical and Humanitarian Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH